| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
EGFR (ErbB1) and HER2 (ErbB2) tyrosine kinases.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
Lapatinib inhibits purified EGFR and HER2 tyrosine kinases with IC50 values of approximately 10.8 nM and 9.2 nM, respectively. In cell-based assays, it inhibits the growth of EGFR-overexpressing A431 skin cancer cells and HER2-amplified BT474 breast cancer cells with IC50 values in the nanomolar range. It also inhibits receptor autophosphorylation in these cells. |
| ln Vivo |
In vivo, lapatinib inhibits tumor growth in xenograft models of HER2-positive breast cancer (e.g., BT474, NCI-N87) when administered orally at doses of 30–100 mg/kg/day. It reduces tumor volume and inhibits downstream signaling in tumor tissue. The deuterated form is used for pharmacokinetic analysis.
|
| Enzyme Assay |
EGFR and HER2 kinase assays use recombinant kinase domains and a synthetic peptide substrate. ATP consumption is measured by luciferase-based or fluorescence-based methods, and IC50 values are determined from dose–response curves. Receptor autophosphorylation is measured by ELISA or immunoblotting in treated cells.
|
| Cell Assay |
In vitro cell experiments use A431, BT474, NCI-N87, or SK-BR-3 cells. Cells are treated with lapatinib (0.1 nM–10 µM) for 1–5 days, and cell viability is assessed by MTT or sulforhodamine B assays. EGFR/HER2 phosphorylation and downstream signaling (AKT, ERK) are analyzed by immunoblotting.
|
| Animal Protocol |
Xenograft models are established by subcutaneous implantation of BT474 or NCI-N87 cells in immunodeficient mice. Lapatinib is administered orally at 30–100 mg/kg/day for 2–4 weeks. Tumor volume is measured with calipers, and tumor tissue is collected for pharmacodynamic analysis. Plasma concentrations are quantified by LC-MS/MS using the d5-labeled internal standard.
|
| References |
|
| Molecular Formula |
C29H21D5CLFN4O4S
|
|---|---|
| Molecular Weight |
586.09
|
| CAS # |
2748212-14-6
|
| Related CAS # |
Lapatinib;231277-92-2
|
| Appearance |
Typically exists as solid at room temperature
|
| SMILES |
O=S(CC([2H])([2H])NCC1=CC=C(C2=CC=C3C(C(NC4=CC(Cl)=C(C=C4)OCC5=CC(F)=CC=C5)=NC=N3)=C2)O1)(C([2H])([2H])[2H])=O
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7062 mL | 8.5311 mL | 17.0622 mL | |
| 5 mM | 0.3412 mL | 1.7062 mL | 3.4124 mL | |
| 10 mM | 0.1706 mL | 0.8531 mL | 1.7062 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.